BOSTON--(BUSINESS WIRE)--Second Sight Medical Products Inc, a leading developer of retinal prostheses for treating blindness, announced today that it has completed enrollment of the first phase of a US FDA approved clinical study of the ArgusTM II Retinal Prosthesis System. The company also announced that enrollment at key European sites is underway as studies continue in Mexico.
